Keyphrases
Atezolizumab Plus Bevacizumab
100%
Survival Prediction
100%
Prognostic nutritional Index
100%
Advanced Hepatocellular Carcinoma
100%
Overall Survival
25%
Progression-free Survival
25%
Independent Prognostic Factor
16%
Hepatocellular Carcinoma Patients
16%
Higher Groups
16%
Clinical Outcomes
8%
Multivariate Analysis
8%
Lenvatinib
8%
Sorafenib
8%
Univariate Analysis
8%
Objective Response Rate
8%
Receiver Operating Characteristic Analysis
8%
Lymphocytes
8%
Disease Control Rate
8%
Hepatocellular Carcinoma
8%
First-line Therapy
8%
Albumin
8%
Serum Albumin Concentration
8%
Albumin Level
8%
Blood Levels
8%
Prognostic Role
8%
Lymphocyte Count
8%
Multicentric
8%
Gastrointestinal Neoplasms
8%
Peripheral Lymphocyte Count
8%
Multiparametric Scores
8%
Pharmacology, Toxicology and Pharmaceutical Science
Liver Cell Carcinoma
100%
Atezolizumab
100%
Bevacizumab
100%
Overall Survival
75%
Progression Free Survival
75%
Serum Albumin
25%
Disease
25%
Sorafenib
25%
Lenvatinib
25%
Gastrointestinal Tumor
25%
Medicine and Dentistry
Hepatocellular Carcinoma
100%
Atezolizumab
100%
Bevacizumab
100%
Nutrition Assessment
100%
Overall Survival
25%
Progression Free Survival
25%
Prognostic Factor
16%
Lymphocyte
16%
Serum Albumin
8%
Disease
8%
Multivariate Analysis
8%
Lenvatinib
8%
Sorafenib
8%
Univariate Analysis
8%
Gastrointestinal Tumor
8%
Peripheral Lymphocyte
8%
Immunology and Microbiology
Atezolizumab
100%
Bevacizumab
100%
Progression Free Survival
75%
Overall Survival
75%
Lymphocyte Count
50%
Albumin Level
25%
Lenvatinib
25%
Blood Level
25%
Sorafenib
25%
Lymphocyte
25%